HIV prevention pill records 100% success rate
Nigeria to begin study on pre-exposure prophylaxis in Nnewi, Calabar, Jos • NACA roundtable calls for nationwide introduction of novel drug A new study has found that 100 per cent of participants taking Human Immuno-deficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) prevention pill remained infection free. The study conducted at Kaiser Permanente in San Francisco, United States (U.S.) involved more than 600 high-risk individuals, most of whom were men who have sex with men. These individuals were healthy at the time of enrollment and were put on a daily regimen of a blue pill called Truvada as a pre-exposure prophylaxis (PrEP). Lead author Jonathan Volk, a physician and epidemiologist at Kaiser Permanente San Francisco Medical Center, described the study as “the first to extend the understanding of the use of PrEP in a real-world setting and suggests that the treatment may prevent new HIV infections even in a high-risk setting.” The U.S. Centers...